Lung Cancer

The FDA has granted a breakthrough therapy designation to JNJ-61186372 for the treatment of patients with EGFR-positive metastatic non–small cell lung cancer who harbor exon 20 insertion mutations, and whose disease has progressed on or after platinum-based chemotherapy.

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

Michael K. Gould, MD, MS, discusses pivotal lung cancer screening trials and their impact on clinical practice.

Ronald B. Natale, MD, medical director, Clinical Lung Cancer Program and assistant clinical professor of medicine, Cedars-Sinai, discusses the utility of PD-L1 expression and tumor mutational burden (TMB) in lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer

Kavitha Ramchandran, MD, discusses considerations as patients with thoracic malignancies enter palliative care.

Zofia Piotrowska, MD, MHS, discusses the patient populations eligible to receive osimertinib as treatment for lung cancer.

Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.

Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.

Alain C. Mita, MD, discusses the impact of immunotherapy in the frontline and recurrent settings for patients with small cell lung cancer.

The FDA's Oncologic Drugs Advisory Committee voted 6 to 5 in favor of intravenous ramucirumab injection for use in combination with erlotinib as a frontline treatment for patients with metastatic non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.

Kathryn E. Hudson, MD, and Jeff Yorio, MD, discuss when it is appropriate to wait for testing before starting therapy, the accuracy of tumor and liquid biopsies, as well as optimal sequencing strategies when managing patients with brain metastases.

The FDA has granted a priority review designation to a supplemental New Drug Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

Osimertinib, at 160 mg daily, demonstrated efficacy in the central nervous system and a manageable safety profile in patients with EGFR-mutant advanced non–small cell lung cancer who have leptomeningeal metastases.

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Ronald Natale, MD, expands on the recent developments with immunotherapy in advanced non–small cell lung cancer.